APR 2 5 2006 Under Re

04/26/20 02 FC:18 PTO/SB/26 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

~ NOTERMIN	AL DISCLAIMER TO OBVIATE A DOUBLE PATENTING	Docket Number (Optional)
MAGEN	REJECTION OVER A "PRIOR" PATENT	1488.115000P/EKS/HCC
In re Application of:	Li et al.	
Application No.:	10/791,905	
Filed:	March 4, 2004	
For:	Human G-Protein Chemokine Receptor (CCR5) HDGNR10	
except as provided the expiration date of and 173, and as the granted on the insta	below the terminal part of the statutory term of any patent granted on the instant	prior patent is defined in 35 U.S.C. 154 owner hereby agrees that any patent so prior patent are commonly owned. This
would extend to the patent is presently sexpires for failures is held unenform is found invalid is statutorily dishas all claims of is reissued; or	disclaimer, the owner does not disclaim the terminal part of the term of any patent expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the shortened by any terminal disclaimer," in the event that said prior patent later: re to pay a maintenance fee; ceable; by a court of competent jurisdiction; claimed in whole or terminally disclaimed under 37 CFR 1.321; anceled by a reexamination certificate; er terminated prior to the expiration of its full statutory term as presently shortened to	prior patent, "as the term of said prior
Check either box 1 o	or 2 below, if appropriate.	
	sions on behalf of a business/organization (e.g., corporation, partnership, university idersigned is empowered to act on behalf of the business/organization.	r, government agency,
belief are believed t	eclare that all statements made herein of my own knowledge are true and that a o be true; and further that these statements were made with the knowledge that e by fine or imprisonment, or both, under Section 1001 of Title 18 of the United pardize the validity of the application or any patent issued thereon.	willful false statements and the like so
2. X The unders	signed is an attorney or agent of record. Reg. No. 47,473	
	Mulenllarbon	April 25, 2006
	Signature	Date
	Helene C. Carlson	
)6 NNGUYEN1 000001	Typed or printed name	
	130.00 OP	(202) 371-2600
14	TOAS AA OL	Telephone Number
X Terminal	disclaimer fee under 37 CFR 1.20(d) included.	
	WARNING: Information on this form may become public. Credit card inform be included on this form. Provide credit card information and authorization	ation should not on PTO-2038.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the properties of th

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.